van den Bosch T, Rueda OM, Caldas C, Vermeulen L, et al. Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy. Br J Cancer 2022 Jul 21. pii: 10.1038/s41416-022-01906.
PMID: 35864159